Skip to main content

Site notifications

ZINNAT cefuroxime axetil 125 mg/5 mL granules for oral suspension (UK)

Section 19A approved medicine
ZINNAT cefuroxime axetil 125 mg/5 mL granules for oral suspension (UK)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0422 429 648
Approved until
Status
Current
Medicines in short supply/unavailable
ZINNAT cefuroxime 125 mg/5mL - ARTG 178687
Indication(s)

Treatment of the following mild to moderately severe infections caused by sensitive bacteria in paediatric patients aged 3 months to 12 years: tonsillitis and pharyngitis, acute bacterial otitis media. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefuroxime axetil appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime axetil in the subsequent prevention of rheumatic fever are not available at present.

Images
Picture of ZINNAT cefuroxime axetil 125 mg/5 mL granules for oral suspension (UK)

Help us improve the Therapeutic Goods Administration site